ERIS Lifesciences Ltd News
BSE MidCap, SmallCap rebound 3% from day's low; TTML, Kaynes soar up to 20%
Shares of Kaynes Technology were up 14 per cent at ₹4,328 on the BSE in intra-day trade as the stock recovered 17 per cent from its 52-week low of ₹3,713.75 hit today.
 "BSE MidCap, SmallCap rebound 3% from day's low; TTML, Kaynes soar up to 20%")
Eris Lifesciences to acquire 30% stake in Swiss Parenterals for ₹423 cr
Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control
 "Eris Lifesciences to acquire 30% stake in Swiss Parenterals for ₹423 cr")
Eris Lifesciences to acquire balance 30% stake in Swiss Parenterals
Eris Lifesciences on Tuesday said its board has approved the acquisition of the remaining 30 pc stake in its subsidiary Swiss Parenterals. The proposed transaction will be effected as a share swap, through a preferential issuance of the company's shares to seller Naishadh Shah, thereby making him a shareholder and an integral part of the company's senior management team with long-term alignment, the Mumbai-based firm said in a statement. "On behalf of the shareholders of Eris, I am delighted to welcome Naishadh Shah to the community of Erisians. I am also happy to share that we propose to designate him as the Managing Director of Swiss Parenterals," Eris Lifesciences Chairman and Managing Director Amit Bakshi said. FY27 promises to be a breakout year for the company's international business, and Naishadh's continued leadership and stewardship will be pivotal to its growth, he added. Shares of Eris Lifesciences were trading 0.99 per cent down at Rs 1,665.20 apiece on the BSE.
 "Eris Lifesciences to acquire balance 30% stake in Swiss Parenterals")
PL Capital sees Nifty at 28,781 in 1 yr; banks, auto, defence to lead rally
Analysts at PL Capital expect domestic-oriented sectors to outperform, naming banks, NBFCs, autos, retail, consumer staples, defence, metals, and select consumer durables as top picks.
 "PL Capital sees Nifty at 28,781 in 1 yr; banks, auto, defence to lead rally")
Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally
Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.
 "Pfizer soars 8%; Sun, Lupin gain up to 4%; here's what triggered the rally")
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Eris Lifesciences to leverage Novo Nordisk's exit and semaglutide patent expiry, with cartridge capacity and diabetes-focused products planned for commercialisation in FY26
